🧬 Fast Facts: Siponimod and CYP2C9 Genotyping
Why it matters:
Pre-emptive pharmacogenomic testing helps reduce adverse drug reactions.
🩺 Medication:
Siponimod (Kiendra™) is now registered in South Africa for treating Secondary Progressive Multiple Sclerosis (SPMS).
⚠️ Contraindication:
Patients with the **CYP2C9 3/3 genotype (poor metabolisers) should not use Siponimod due to elevated plasma levels.
🧬 Testing Information
- 🧪 CYP2C9 genotyping is available at Ampath.
- 🧬 Included in the comprehensive pharmacogenomics panel (Test Mnemonic: PHARMA).
- ⏱️ Results available within 10 working days.
- 📧 For more info: pgx@ampath.co.za
🧬 Pathology Solutions Are in Our DNA
🔗 ampath.co.za